From the aDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands
bEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France
cDepartment of Epidemiology and Surveillance, National Institute of Public Health and the Environment (RIVM), Bilthoven, the Netherlands
dAmsterdam UMC, University of Amsterdam, Internal Medicine, Amsterdam Institute for Infection and Immunity (AII), Amsterdam, the Netherlands.
Submitted February 6, 2022; accepted September 15, 2022
M.F. Schim van der Loeff received research funding from Sanofi Pasteur MSD; he was a co-investigator in a Merck-funded investigator-initiated study on Gardasil; he was an investigator on a Sanofi Pasteur MSD sponsored HPV vaccine trial; he served on advisory boards of GSK and Merck; he received in-kind contribution for another study from Stichting Pathologie Onderzoek en Ontwikkeling (SPOO); his institution received research funding from Janssen Infectious Diseases and Vaccines. The other authors report no conflicts of interest. The authors are solely responsible for final content and interpretation.
Due to the sensitive nature of the data, data can be requested from the corresponding author or [email protected] at reasonable request.
SDC Supplemental digital content is available through direct URL citations in the HTML and PDF versions of this article (www.epidem.com).
Correspondence: Eline Wijstma, Nieuwe Achtergracht 100, 1018WT Amsterdam, the Netherlands, +31 20 555 5083. E-mail: [email protected].
